# Research Pulse — 2026-09-28 _Generated 2026-09-28 07:34 KST · AI × Bioresearch Daily synthesis_ Brown Biotech daily research pulse — multi-front synthesis across CRISPR / gene editing, AI drug discovery, protein AI, single-cell foundation models, FDA/regulatory, and spatial transcriptomics. Sources: company filings, peer-reviewed journals, FDA guidance, conference disclosures. --- ### Post 1: 오늘의 전체 흐름 🧬 **AI × Bioresearch Daily — 9월 28일 (월요일) · Institutionalizing(제도화) Day** 9/28(제도화) → 9/27(성숙) → 9/26(번역) → 9/25(시너지) → 9/24(확장) → 9/23(진전) → 9/22(집적화) → 9/21(정상화). Maturation(9/27)된 기술들이 **FDA platform-aligned regulatory framework의 제도화·AI pharma partnership의 상업적规模化·base editing의 표준화된 고효율 프로토콜 확립·spatial atlas의 임상 구현 단계 등 기술이 pioneering 성과에서 제도화된 반복 가능한 classe로 전환되며, 산업 표준과 규제 프레임워크로 안착하는 Institutionalizing 단계로 이전하며, 기술이 혁신이 아닌 제도적 기반의 차원에서 안정화되는 날** — Luo et al.로 HMGN1+VP64 fusion base editing — SpRY PAM-flexible + yeast/rice 적용 확인 + high-precision low-off-target (Advanced Science 2026), Cho et al.로 multiplexed base editing biocontainment — eEGM module + essential gene inactivation + NIH escape frequency criterion 충족 (Nucleic Acids Research 2026), Lin et al.로 2026 pharma AI deal flurry — big pharma AI platform 투자 급증 + Isomorphic Labs·Exscientia·Recursion 투자 동향 (GEN Biotechnology 2026), DenAdel et al.로 single-cell FM plateau — 22.2M cells 400 models 6,400 experiments + scaling law 부재 확인 (Nature Methods 2026), Sarti et al.로 AlphaFold quality arity map — whole proteome assessment + physically implausible predictions flagging (Bioinformatics Advances 2026), Zhang et al.로 CosMx SCLC spatial — 75 patients 600K cells + vascular-immune crosstalk + pan-immune hotspot survival predictor (Cell Reports Medicine 2026)가 동시에 진행된다. Institutionalizing은 Maturation의 다음 단계다. 오늘 6개 전선은 성숙된 기술들이 **제도적 기반, 산업 표준, 규제 프레임워크로 안착하며, pioneering innovation에서 제도화된 repeatable classe로 안정화되는 날**이다. *출처: [Luo HMGN1 VP64 Base Editing Advanced Science 2026](https://consensus.app/papers/details/dae4b67891e95542883889f62a6beba6/), [Cho Multiplexed Biocontainment Nucleic Acids Research 2026](https://consensus.app/papers/details/35db4acf11255ff291d15b84ac3a7d62/), [Lin Pharma AI 2026 Deals GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/), [DenAdel Single-Cell FM Plateau Nature Methods 2026](https://consensus.app/papers/details/f0f6bddc16985563ad8478918950e0f4/), [Sarti AlphaFold Arity Map Bioinformatics Advances 2026](https://consensus.app/papers/details/97d0d09907ed559998afbc1980b532f3/), [Zhang CosMx SCLC Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/)* *#InstitutionalizingDay #Luo #AdvancedScience #BaseEditing #PAMFlexible #SpRY #HMGN1 #VP64 #Yeast #Rice #Cho #NucleicAcidsResearch #Biocontainment #eEGM #EssentialGene #NIH #Lin #GEnBiotechnology #PharmaAI #2026Deals #DenAdel #NatureMethods #SingleCell #FoundationModel #Plateau #NoScalingLaw #Sarti #BioinformaticsAdvances #AlphaFold #ArityMap #QualityAssessment #Zhang #CellReportsMedicine #CosMx #SCLC #VascularImmune #PanImmuneHotspot #Institutionalizing #RegulatoryFramework #IndustryStandard #BiomedicalAI #DailyReport* --- ### Post 2: CRISPR & Gene Editing — PAM-Flexible Base Editing × Biocontainment: Institutionalizing 🪄 **[CRISPR/Gene Editing] Luo et al.로 HMGN1+VP64 fusion base editing — SpRY PAM-flexible + truncated CDA1 + yeast/rice 적용 확인 + high-precision low-off-target (Advanced Science 2026) + Cho et al.로 multiplexed base editing biocontainment — eEGM module + essential gene inactivation + NIH escape frequency criterion ≤10⁻⁸ (Nucleic Acids Research 2026): CRISPR Institutionalizing(제도화) 동시 확인** CRISPR base editing의 **표준화된 고효율 프로토콜 확립 + 산업적 응용 분야 제도화(Institutionalizing)**가 출처에서 동시에 확인된다[1][2]. **HMGN1+VP64 Fusion Base Editing: PAM-Flexible High-Precision Across Species[1]** Xi Luo et al.(Advanced Science 2026)의 연구는 SpRY near-PAM-less Cas9 variant와 truncated CDA1 cytidine deaminase 결합으로 PAM 제약을 극복하는 base editing 전략을 제시한다[1]. **핵심 성과 1 — HMGN1+VP64 synergistic fusion**: DNA-binding protein library screen으로 편집 활성 향상 확인. **핵심 성과 2 — High precision without compromising specificity**: off-target effect 현저히 증가 없이 효율 향상. **핵심 성과 3 — Yeast 적용 확인**: 세포 치료·유전자 치료 기본 연구 도구로서 적용 가능성. **핵심 성과 4 — Rice 적용 확인**: precision breeding 응용 가능성. **핵심 성과 5 — SpRY + truncated CDA1 combination**: virtually any cytosine in genome 편집 가능. **핵심**: HMGN1+VP64 fusion으로 PAM-flexible high-precision base editing 표준화 — CRISPR Institutionalizing Consolidating. **Multiplexed Base Editing Biocontainment: eEGM Module + NIH Criterion 충족[2]** S. Cho et al.(Nucleic Acids Research 2026)의 연구는 CRISPR-mediated cytidine base editing으로 engineered bacteria의 불가역적 자기사멸 시스템을 제시한다[2]. **핵심 성과 1 — eEGM module**: editing-driven essential gene multiplex inactivation. **핵심 성과 2 — Single transient induction으로 불가역적 사멸**: start codon targeting으로 translation blockade. **핵심 성과 3 — NIH guideline criterion 충족**: escape frequency ≤10⁻⁸ within 1h induction. **핵심 성과 4 — 세 가지 비잔역성 필수 유전자 동시 표적**: holA, ftsB, dfp. **핵심 성과 5 — laboratory·industrial·therapeutic E. coli strains 광범위 적용**: MG1655, W3110, Nissle 1917. **핵심 성과 6 — Heterologous protein expression 무干扰**: engineered microbes 산업적 활용 가능성. **핵심**: multiplexed base editing으로 pulse-activated irreversible biocontainment 제도화 — CRISPR 산업 적용 Institutionalizing. **9월 27일 Maturation(Şahin CRISPR trajectory + Chakraborty approval landscape) vs 오늘의 차별점**: 9/27이 Şahin Molecular Therapy로 CRISPR global trajectory 2023 Casgevy → 2026 CPS1 personalized therapy를, Chakraborty Molecular Therapy로 Casgevy UKMHRA/FDA approval landscape을 제시했다면, 오늘은 같은 CRISPR 분야 내에서 **Luo Advanced Science**으로 **HMGN1+VP64 PAM-flexible base editing 표준화(yeast/rice 적용)**를(표준 프로토콜), **Cho Nucleic Acids Research**으로 **base editing 기반 biocontainment 산업 적용 제도화(NIH criterion 충족)**를(산업 응용) 동시에 제시한다. Maturation(9/27) → 표준 프로토콜 + 산업 적용 Institutionalizing(9/28). 실무 함의: 유전자 치료 플랫폼팀에서 Luo et al.의 PAM-flexible base editing 표준화 프로토콜을 분석하여 조직 특이적 편집 전략을 수립해야 한다. *출처: [Luo HMGN1 VP64 Base Editing Advanced Science 2026](https://consensus.app/papers/details/dae4b67891e95542883889f62a6beba6/), [Cho Multiplexed Biocontainment Nucleic Acids Research 2026](https://consensus.app/papers/details/35db4acf11255ff291d15b84ac3a7d62/)* *#CRISPR #BaseEditing #Luo #AdvancedScience #HMGN1 #VP64 #SpRY #PAMFlexible #PAMLess #CDA1 #HighPrecision #LowOffTarget #Yeast #Rice #PrecisionBreeding #Cho #NucleicAcidsResearch #eEGM #Biocontainment #EssentialGene #Multiplex #NIH #EscapeFrequency #Institutionalizing #StandardProtocol #IndustrialApplication #GeneTherapy #Biomanufacturing* --- ### Post 3: AI 신약 — 2026 Pharma AI Deal Flurry + AI Agent Pipeline Integration: Institutionalizing 💊 **[AI 신약] Lin et al.로 2026 pharma AI deal flurry — big pharma AI platform 투자 급증 + Isomorphic Labs·Exscientia·Recursion Pharologi 투자 동향(GEN Biotechnology 2026) + Huynh et al.로 AI agents in drug discovery — literature synthesis·toxicity prediction·synthesis·end-to-end decision-making pipeline 체계화(Drug Discovery Today 2026) + AI-driven preclinical pipeline의 제도화된 통합 체계 확인: AI drug discovery Institutionalizing(제도화) 동시 확인** AI-driven drug discovery의 **pharma-industry partnership 제도화 + AI agent pipeline 표준화(Institutionalizing)**가 출처에서 동시에 확인된다[3][4]. **2026 Pharma AI Deal Flurry: Big Pharma AI Platform 투자 급증[3]** Fay Lin(GEN Biotechnology 2026)의 기사는 2026년 pharma AI partnership 투자 급증세를 분석한다[3]. **Isomorphic Labs**: Google DeepMind 산하 구조biology AI company. **Exscientia**: AI-first drug discovery company. **Recursion Pharologi**: automated biology platform. **핵심**: 2026년 big pharma가 AI platform에 대규모 투자 — AI drug discovery의 산업적 제도화. **AI Agents in Drug Discovery: End-to-End Pipeline Integration[4]** Dinh-Long Huynh et al.(Drug Discovery Today 2026)의 review는 AI agent architecture의 drug discovery pipeline 적용을 종합한다[4]. **핵심 성과 1 — Literature synthesis**: 자동화된 문헌 분석. **핵심 성과 2 — Automated protocol generation**: 실험 프로토콜 자동 생성. **핵심 성과 3 — Toxicity prediction**: 사전 임상 독성 예측. **핵심 성과 4 — Small-molecule synthesis automation**: 분자 합성 자동화. **핵심 성과 5 — Drug repurposing**: 약물 재창출 AI. **핵심 성과 6 — End-to-end decision-making**: 전체 의사결정 과정 자동화. **Early implementations**: substantial gains in speed, reproducibility, scalability. **Challenges**: data heterogeneity, system reliability, privacy, benchmarking. **핵심**: AI agents로 drug discovery pipeline의 제도화된 통합 — AI drug discovery Institutionalizing. **9월 26일 Translating(Mao Phase IIa efficacy + AI Phase IIa 1건/Phase I 1건) vs 오늘의 차별점**: 9/26이 Mao Frontiers in Pharmacology로 AI drug discovery 임상 번역 첫 성과(Phase IIa efficacy success)를 제시했다면, 오늘은 **Lin GEN Biotechnology**으로 **2026 pharma AI deal flurry(산업 투자 급증)**를(자본 참여 제도화), **Huynh Drug Discovery Today**으로 **AI agent pipeline의 end-to-end 통합 체계**를(프로세스 제도화) 동시에 제시한다. Translating(9/26) → partnership + pipeline Institutionalizing(9/28). 실무 함의: AI drug discovery 협업팀에서 Lin et al.의 2026 pharma AI deal 동향을 분석하여 partnership strategy를 수립해야 한다. *출처: [Lin Pharma AI 2026 Deals GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/), [Huynh AI Agents Drug Discovery Drug Discovery Today 2026](https://consensus.app/papers/details/d47b0cf47a4f5055a7175a6fe09bb6e4/)* *#AI #DrugDiscovery #Lin #GENBiotechnology #PharmaAI #2026Deals #IsomorphicLabs #Exscientia #Recursion #Huynh #DrugDiscoveryToday #AIAgent #PipelineIntegration #LiteratureSynthesis #ToxicityPrediction #SynthesisAutomation #EndToEnd #Institutionalizing #BigPharma #Partnership #IndustryStandard #DrugRepurposing* --- ### Post 4: 단백질 AI — AlphaFold Quality Arity Map + Oligomeric State Prediction: Institutionalizing 🔬 **[단백질 AI] Sarti et al.로 AlphaFold quality arity map — whole proteome assessment + physically implausible predictions flagging + arity-based structural arrangement quality(Arity-Q) (Bioinformatics Advances 2026) + Lin et al.로 AlphaFold2/3 oligomeric state prediction — 4,700+ proteins 분석 + reliable predictions majority + training data dependency (Protein Science 2026) + Chakraborty et al.로 AlphaFold3 evolution transformative impact review — AF1→AF2→AF3 architectural evolution + Nobel Prize impact (Frontiers AI 2026): 단백질 AI Institutionalizing(제도화) 동시 확인** 단백질 AI의 **품질 평가 표준 프레임워크 확립 + 구조 예측 정확성 제도화(Institutionalizing)**가 출처에서 동시에 확인된다[5][6][7]. **AlphaFold Quality Arity Map: Whole Proteome Assessment + Physically Implausible Predictions Flagging[5]** Edoardo Sarti et al.(Bioinformatics Advances 2026)의 연구는 AlphaFold predictions의 전체 proteome 차원 품질 평가를 위한 arity map 방법을 제시한다[5]. **핵심 성과 1 — 세 가지 구조적 집단 분류**: well-folded proteins, intrinsically disordered proteins, physically implausible predictions. **핵심 성과 2 — Arity-Based Structural Arrangement Quality(Arity-Q)**: per-residue scoring function. **핵심 성과 3 — Hallucinated helices·distorted beta strands flagging**: pLDDT 한계 극복. **핵심 성과 4 — Wasserstein PCA 기반 embedding**: 구조적 특성 2D visualization. **핵심 성과 5 — Native-like predictions 올바르게 scoring**: 기존 방법 대비 개선. **핵심**: AlphaFold quality assessment의 표준 프레임워크 확립 — 단백질 AI Institutionalizing Consolidating. **AlphaFold2/3 Oligomeric State Prediction: 4,700+ Proteins + Training Data Dependency[6]** Yiechang Lin et al.(Protein Science 2026)의 연구는 AlphaFold2-Multimer와 AlphaFold3의 homooligomerisation 예측 정확도를 체계적으로 평가한다[6]. **핵심 성과 1 — 4,700+ proteins 분석**: soluble·membrane proteins 모두 포함. **핵심 성과 2 — Reliable predictions majority**: 대부분의 경우 정확한 예측. **핵심 성과 3 — Training data dependency**: close structural representatives 없는 경우 정확도 제한. **핵심 성과 4 — Multiple physiologically relevant assemblies 가능성**: 일부 단백질에서 복수 assembly 상태. **핵심 성과 5 — Practical guidance 제시**: computational cost 최소화 + challenging cases identification. **핵심**: AlphaFold oligomeric state prediction의 정확도边界 확립 — 단백질 AI 예측 신뢰성 Institutionalizing. **AlphaFold3 Transformative Impact: Architectural Evolution + Nobel Prize[7]** Chakraborty, Bhattacharya & Lee(Frontiers in AI 2026)의 review는 AlphaFold 1→2→3의 architectural evolution과 translational research impact를 종합한다[7]. **AF1→AF2→AF3**: DNN → Evoformer → Pairformer 아키텍처 진화. **2024 Nobel Prize**: protein structure prediction 분야 인정. **SBDD accelerated**: structure-based drug discovery 가속화. **Challenges**: protein dynamics, multiple conformational states. **핵심**: AlphaFold의 학계 인정 + 산업 적용 확산 — 단백질 AI 제도화. **9월 25일 Synergizing(Singh AlphaFold framework) vs 오늘의 차별점**: 9/25이 Singh Current Opinion으로 AlphaFold drug discovery hierarchical framework를 제시했다면, 오늘은 **Sarti Bioinformatics Advances**으로 **AlphaFold whole proteome quality assessment 표준 프레임워크(arity map)**를(품질 제도화), **Lin Protein Science**으로 **AlphaFold oligomeric state prediction 정확도边界 + training data dependency**를(신뢰성 기준), **Chakraborty Frontiers AI**으로 **AlphaFold3 architectural evolution + Nobel Prize impact**를(제도적 인정) 동시에 제시한다. Synergizing(9/25) → quality standard + accuracy boundaries Institutionalizing(9/28). 실무 함의: 단백질 구조 연구팀에서 Sarti et al.의 Arity-Q scoring을 적용하여 AlphaFold 예측 신뢰성 평가 표준화해야 한다. *출처: [Sarti AlphaFold Arity Map Bioinformatics Advances 2026](https://consensus.app/papers/details/97d0d09907ed559998afbc1980b532f3/), [Lin AlphaFold Oligomeric Protein Science 2026](https://consensus.app/papers/details/cff9b03d33d85cdf8d04f175b025a42c/), [Chakraborty AlphaFold3 Frontiers AI 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/)* *#AlphaFold #ProteinStructure #Sarti #BioinformaticsAdvances #ArityMap #QualityAssessment #ArityQ #NativeLike #Hallucination #Lin #ProteinScience #OligomericState #Multimer #TrainingData #Chakraborty #FrontiersAI #AlphaFold3 #ArchitecturalEvolution #NobelPrize #SBDD #Institutionalizing #StandardFramework #AccuracyBoundaries #Reliability #BiomedicalAI* --- ### Post 5: Single-Cell Multi-Omics Foundation Model — Scaling Plateau + No Scaling Law: Institutionalizing 🧬 **[Single-Cell/Foundation Model] DenAdel et al.로 single-cell FM plateau — 22.2M cells 400 models 6,400 experiments + scaling law 부재 확인 + model capacity/dataset size/computational balance 강조 (Nature Methods 2026) + Ji et al.로 CAPTAIN multimodal — scRNA + 382 proteins 동시 측정 + cross-modality dependencies + zero-shot generalization (Nature Communications 2026) + Wang et al.로 CellVQ 68M cells + SCD module + cell code discretization + interpretability (Nature Communications 2026): single-cell FM Institutionalizing(제도화) 동시 확인** Single-cell foundation model의 **scaling law 부재 확인 + multimodal 통합 표준화 + 해석가능성 프레임워크(Institutionalizing)**가 출처에서 동시에 확인된다[8][9][10]. **Single-Cell FM Plateau: No Scaling Law + 22.2M Cells 400 Models 6,400 Experiments[8]** Alan DenAdel et al.(Nature Methods 2026)의 연구는 single-cell foundation model의 dataset size/diversity와 performance 관계를 대규모 실험적으로 분석한다[8]. **핵심 성과 1 — 22.2M cells pretraining**: 현재 corpora 일부만으로도 plateau 도달. **핵심 성과 2 — 400 models trained**: 체계적 비교. **핵심 성과 3 — 6,400 experiments**: 광범위한 성능 평가. **핵심 성과 4 — No clear scaling laws**: LLM과 달리 단일세포 FM은 명확한 scaling law 없음. **핵심 성과 5 — Model capacity·dataset size·computational resources balance 강조**: 무분별한 증가보다 균형 중요. **핵심**: single-cell FM의 scaling law 부재 확인 + 제도적 연구 설계 가이드라인 확립 — single-cell FM Institutionalizing. **CAPTAIN: Multimodal scRNA + 382 Proteins + Cross-Modality Dependencies[9]** Boya Ji et al.(Nature Communications 2026)의 연구는 scRNA와 surface protein을 동시에 측정하는 multimodal foundation model을 제시한다[9]. **핵심 성과 1 — 4M+ cells pretrained**: concurrently measured transcriptomes + 382 proteins. **핵심 성과 2 — Cross-modality dependencies modeling**: modality 간 의존성 학습. **핵심 성과 3 — Protein imputation·expansion**: protein 수준 추론. **핵심 성과 4 — Cell type annotation·batch harmonization**:下游 task 적용. **핵심 성과 5 — Zero-shot generalization**: unseen conditions 적용 가능. **핵심 성과 6 — COVID-19 severity 관련 immune dynamics**: 생물학적discovery 사례. **핵심**: multimodal scRNA+protein 통합 표준화 — single-cell FM Institutionalizing Consolidating. **CellVQ: 68M Cells + SCD Module + Cell Code Discretization[10]** Jue Wang et al.(Nature Communications 2026)의 연구는 sparsity·heterogeneity·interpretability 문제를 해결하는 single-cell foundation model을 제시한다[10]. **핵심 성과 1 — 68M cells dataset**: 500M parameters. **핵심 성과 2 — Single-Cell Discretization(SCD) module**: "cell code"로 변환. **핵심 성과 3 — Heterogeneity 해결**: 고차원 sparse data 처리. **핵심 성과 4 — Interpretability 향상**: biological discovery 가능. **핵심 성과 5 — CellVQ-Graph**: knowledge graph integration. **핵심**: 해석가능성 표준화 — single-cell FM Institutionalizing. **9월 24일 Scaling(DenAdel FM scaling) vs 오늘의 차별점**: 9/24이 DenAdel Nature Methods로 single-cell FM pretraining dataset scaling(22.2M cells)을 제시했다면, 오늘은 같은 DenAdel paper에서 **scaling law 부재의 제도적 의미**를(연구 설계 가이드라인), **Ji Nature Communications**으로 **CAPTAIN multimodal RNA+protein 통합 표준화**를(모달리티 통합), **Wang Nature Communications**으로 **CellVQ SCD module 해석가능성 프레임워크**를(표준화) 동시에 제시한다. Scaling(9/24) → no scaling law + multimodal + interpretability Institutionalizing(9/28). 실무 함의: 단일세포 연구팀에서 DenAdel et al.의 scaling law 부재 발견을 연구 설계에 반영하여 불필요한 데이터 확장을 방지해야 한다. *출처: [DenAdel Single-Cell FM Plateau Nature Methods 2026](https://consensus.app/papers/details/f0f6bddc16985563ad8478918950e0f4/), [Ji CAPTAIN Multimodal Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Wang CellVQ Nature Communications 2026](https://consensus.app/papers/details/89622623baa35922aaca1c5b88e6ce8b/)* *#SingleCell #FoundationModel #DenAdel #NatureMethods #Plateau #NoScalingLaw #400Models #6400Experiments #Ji #CAPTAIN #NatureCommunications #382Proteins #Multimodal #CrossModality #Wang #CellVQ #SCDModule #CellCode #Interpretability #68MillionCells #500MParameters #Institutionalizing #Standardization #ResearchDesign #BiomedicalAI* --- ### Post 6: Spatial Transcriptomics — CosMx SCLC Vascular-Immune Crosstalk × Breast Cancer Multi-Omics: Institutionalizing 🔬 **[Spatial Transcriptomics] Zhang et al.로 CosMx SCLC spatial — 75 patients 600K cells + LNM-enriched malignant subclusters + vascular-immune crosstalk + pan-immune hotspot PIHs-1 survival predictor (Cell Reports Medicine 2026) + Xiao et al.로 breast cancer spatial multi-omics — TLS + tumor-immune interface + chemotherapy/immunotherapy response prediction + niche-specific combination therapy (Clinical & Translational Oncology 2026): spatial transcriptomics Institutionalizing(제도화) 동시 확인** Spatial transcriptomics의 **SCLC 신종 cancer 적용 + 혈관-면역 교차 신호 체계 + 유방암 임상 적용(Institutionalizing)**가 출처에서 동시에 확인된다[11][12]. **CosMx SCLC Spatial: 75 Patients 600K Cells + Vascular-Immune Crosstalk + Survival Predictor[11]** Zicheng Zhang et al.(Cell Reports Medicine 2026)의 연구는 CosMx Spatial Molecular Imager로 소세포폐암의 공간적 세포 생태계를 규명한다[11]. **핵심 성과 1 — 75 patients 105 specimens**: primary + lymph node metastasis. **핵심 성과 2 — 600,000+ cells profiled**: 고해상도 공간 프로파일링. **핵심 성과 3 — 3개 LNM-enriched malignant subclusters**: distinct metabolic·angiogenic programs. **핵심 성과 4 — Vascular-immune crosstalk**: endothelial cells가 malignant cells 회피하며 cytotoxic T cells과 perivascular niche 형성. **핵심 성과 5 — Pan-immune hotspot PIHs-1**: 독립적 survival predictor. **핵심 성과 6 — Immune exclusion features**: 종양 미세환경 면역 배제 기전. **핵심**: CosMx SCLC 공간적 세포 생태계 규명 + 혈관-면역 교차 신호 체계 확립 — spatial transcriptomics Institutionalizing Consolidating. **Breast Cancer Spatial Multi-Omics: TLS + Tumor-Immune Interface + Response Prediction[12]** Yi Xiao et al.(Clinical & Translational Oncology 2026)의 review는 유방암의 공간적 다중omics 연구를 종합한다[12]. **핵심 성과 1 — Spatial proteomics·transcriptomics·metabolomics 통합**: 종양 미세환경 고해상도 매핑. **핵심 성과 2 — Tertiary lymphoid structures(TLS)**: 예후 biomarker. **핵심 성과 3 — Tumor-immune interface distance**: chemotherapy response prediction. **핵심 성과 4 — Immunotherapy response prediction**: niche-specific combination therapy 설계. **핵심 성과 5 — Fibroblast-rich·immunosuppressive regions targeting**: niche-specific combination therapy. **핵심 성과 6 — Clinical readiness varying**: TLS on H&E sections는 near-implementation; high-dimensional spatial은 standardized protocols·prospective validation 필요. **핵심**: 유방암 공간적 multi-omics의 임상 적용 체계 확립 — spatial transcriptomics Institutionalizing. **9월 25일 Synergizing(Gao gastric cancer spatial atlas) vs 오늘의 차별점**: 9/25이 Gao Nature Communications로 gastric cancer spatial atlas(Lymphocyte Aggregated Region + TLS + PD1+CD8 T proximity)를 제시했다면, 오늘은 **Zhang Cell Reports Medicine**으로 **CosMx SCLC spatial(75 patients 600K cells + vascular-immune crosstalk + PIHs-1)**를(SCLC 신종 cancer type), **Xiao Clinical & Translational Oncology**으로 **breast cancer spatial multi-omics(TLS + tumor-immune + response prediction)**를(또 다른 신종 cancer type) 동시에 제시한다. Synergizing(9/25 gastric) → SCLC + breast cancer Institutionalizing(9/28). 실무 함의: 종양면역 연구팀에서 Zhang et al.의 PIHs-1 survival predictor를肺癌 면역예후 biomarker로 평가해야 한다. *출처: [Zhang CosMx SCLC Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/), [Xiao Breast Cancer Spatial Clinical & Translational Oncology 2026](https://consensus.app/papers/details/860a4566c2235494b7a009a0b9a2c10f/)* *#SpatialTranscriptomics #Zhang #CellReportsMedicine #CosMx #SCLC #600KCells #75Patients #VascularImmune #Crosstalk #EndothelialCells #CytotoxicT #PanImmuneHotspot #PIHs1 #SurvivalPredictor #LymphNodeMetastasis #Xiao #ClinicalTranslationalOncology #BreastCancer #SpatialMultiOmics #TLS #TertiaryLymphoidStructures #TumorImmuneInterface #ChemotherapyResponse #ImmunotherapyResponse #NicheSpecific #FibroblastRich #Institutionalizing #ClinicalTranslation #PrecisionOncology* --- ### Post 7: FDA/규제 — CGT Approval 38개 Evidence Assessment + Pediatric Clinical Pharmacology: Institutionalizing 📋 **[FDA/규제] Shahzad et al.로 FDA CGT 38개 approval evidence assessment — 86.8% orphan designation + 92.1% expedited pathway + 73.7% single pivotal study + 44.7% surrogate endpoints only + 73.4% PMR/PMC (Clinical Pharmacology & Therapeutics 2026) + Kunanayagam et al.로 pediatric CGT clinical pharmacology — 44 approvals 14 pediatric + PK considerations + vector shedding·biodistribution + preclinical modeling (Pediatric Research 2026): FDA/규제 Institutionalizing(제도화) 동시 확인** FDA gene therapy regulatory framework의 ** evidence assessment 체계화 + pediatric 적용 표준화(Institutionalizing)**가 출처에서 동시에 확인된다[13][14]. **FDA CGT 38개 Approval Evidence Assessment: Single Study + Surrogate Endpoints + PMR[13]** Mahnum Shahzad et al.(Clinical Pharmacology & Therapeutics 2026)의 연구는 FDA 승인 CGT 38개(1998년~2025년 12월)의 evidence profile을 체계적으로 분석한다[13]. **핵심 성과 1 — 86.8% orphan designation**: 희귀질환 대상. **핵심 성과 2 — 92.1% expedited pathway**: 신속 심사 활용. **핵심 성과 3 — 73.7% single pivotal study**: 단일 임상시험 기반 승인. **핵심 성과 4 — 44.7% surrogate endpoints only**: 대리 конечная 점 only. **핵심 성과 5 — 73.4% PMR/PMC**: 승인 후 제조 후 요구사항. **핵심 성과 6 — 17.9% primary clinical efficacy endpoint**: 승인 후 임상疗效 endpoint 포함. **핵심 성과 7 — Most studies ongoing**: 승인 후 후속 연구 진행 중. **핵심**: FDA CGT approval evidence profile의 제도화된 평가 체계 확립 — FDA/규제 Institutionalizing Consolidating. **Pediatric CGT Clinical Pharmacology: 44 Approvals 14 Pediatric + Preclinical Modeling[14]** S. Kunanayagam et al.(Pediatric Research 2026)의 review는 소아 CGT의 임상약물학적 특성을 분석한다[14]. **핵심 성과 1 — 44 approvals 14 pediatric**(cord blood 제외). **핵심 성과 2 — In vivo gene therapy**: vector shedding·biodistribution 고려. **핵심 성과 3 — Ex vivo gene therapy**: cellular kinetics(expansion·persistence) relevant. **핵심 성과 4 — CAR-T·TIL**: 세포 kinetics 특이적. **핵심 성과 5 — Preclinical modeling 의존**: dose selection·safety 평가. **핵심 성과 6 — Rare disease·pediatric challenges**: 소규모 환자 집단. **핵심**: 소아 CGT 임상약물학 표준 프레임워크 확립 — FDA/규제 Institutionalizing. **9월 27일 Maturation(Oo FDA 38개 approval + platform-aligned) vs 오늘의 차별점**: 9/27이 Oo J Clinical Pharmacology로 FDA gene therapy 38개 approval platform-aligned risk-based framework를 제시했다면, 오늘은 **Shahzad Clinical Pharmacology & Therapeutics**으로 **evidence assessment 체계(86.8% orphan + 73.7% single study + 44.7% surrogate)**를(승인 evidence profile), **Kunanayagam Pediatric Research**으로 **pediatric CGT clinical pharmacology 표준 프레임워크**를(소아 적용 표준화) 동시에 제시한다. Maturation(9/27) → evidence assessment + pediatric Institutionalizing(9/28). 실무 함의: Regulatory Affairs팀에서 Shahzad et al.의 evidence assessment framework를 CGT approval 전략에 반영해야 한다. *출처: [Shahzad FDA CGT Evidence Assessment Clinical Pharmacology & Therapeutics 2026](https://consensus.app/papers/details/24705d5037e85bcb9d9863f1aabca040/), [Kunanayagam Pediatric CGT Pediatric Research 2026](https://consensus.app/papers/details/1c13548ad5be537a8451eed2c85ecd75/)* *#FDA #GeneTherapy #Regulatory #Shahzad #ClinicalPharmacologyTherapeutics #38Approvals #OrphanDesignation #ExpeditedPathway #SinglePivotalStudy #SurrogateEndpoints #PMR #PMC #Kunanayagam #PediatricResearch #Pediatric #CAR-T #TIL #VectorShedding #Biodistribution #CellularKinetics #PreclinicalModeling #Institutionalizing #EvidenceAssessment #StandardFramework #BiomedicalAI* --- ### Post 8: 오늘의 요약 — Institutionalizing(제도화) Day 총정리 🧬 **Institutionalizing(제도화) 핵심 요약 — 9월 28일** 오늘 Institutionalizing Day의 6개 전선 핵심: **1. CRISPR(제도화)**: HMGN1+VP64 fusion으로 PAM-flexible base editing 표준화 + eEGM multiplexed base editing으로 biocontainment 산업 적용 제도화(NHS ≤10⁻⁸) [1][2] **2. AI Drug Discovery(제도화)**: 2026 pharma AI deal flurry(Isomorphic Labs·Exscientia·Recursion) + AI agent pipeline end-to-end 통합(literature→toxicity→synthesis→decision) [3][4] **3. 단백질 AI(제도화)**: AlphaFold whole proteome quality arity map(Arity-Q) 표준 프레임워크 + AlphaFold oligomeric state prediction 정확도 boundary + AF3 Nobel Prize 인정 [5][6][7] **4. Single-Cell FM(제도화)**: 단일세포 FM scaling law 부재 확인(400 models 6,400 experiments) + CAPTAIN multimodal RNA+protein 통합 + CellVQ SCD cell code 해석가능성 [8][9][10] **5. Spatial Transcriptomics(제도화)**: CosMx SCLC 75 patients 600K cells vascular-immune crosstalk + PIHs-1 survival predictor + breast cancer spatial multi-omics TLS+immunotherapy [11][12] **6. FDA/규제(제도화)**: FDA CGT 38개 approval evidence assessment(73.7% single study + 44.7% surrogate) + pediatric CGT clinical pharmacology 표준 프레임워크 [13][14] 오늘은 **Maturation(Maturation)에서 Institutionalizing(제도화)로 이행하는 날**: pioneering innovation이 제도화된 repeatable classe로 안정화되며, regulatory framework·industry standard·quality benchmark가 확립되는 날이다. **직전 4일(9/24-27) 대비 차별화**: CRISPR에서 PAM-flexible base editing(yeast/rice 적용)과 biocontainment 응용, AI drug discovery에서 2026 pharma AI deal flurry와 AI agent pipeline, 단백질 AI에서 arity-based quality scoring, single-cell FM에서 scaling law 부재 발견과 multimodal 통합, spatial에서 SCLC와 유방암 신종 cancer type 적용이 새로운 차별점이다. *출처: [Luo HMGN1 VP64 Base Editing](https://consensus.app/papers/details/dae4b67891e95542883889f62a6beba6/), [Cho Biocontainment](https://consensus.app/papers/details/35db4acf11255ff291d15b84ac3a7d62/), [Lin Pharma AI 2026 Deals](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/), [Huynh AI Agents](https://consensus.app/papers/details/d47b0cf47a4f5055a7175a6fe09bb6e4/), [Sarti AlphaFold Arity Map](https://consensus.app/papers/details/97d0d09907ed559998afbc1980b532f3/), [Lin AlphaFold Oligomeric](https://consensus.app/papers/details/cff9b03d33d85cdf8d04f175b025a42c/), [Chakraborty AlphaFold3](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/), [DenAdel Single-Cell FM](https://consensus.app/papers/details/f0f6bddc16985563ad8478918950e0f4/), [Ji CAPTAIN](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Wang CellVQ](https://consensus.app/papers/details/89622623baa35922aaca1c5b88e6ce8b/), [Zhang CosMx SCLC](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/), [Xiao Breast Cancer](https://consensus.app/papers/details/860a4566c2235494b7a009a0b9a2c10f/), [Shahzad FDA CGT](https://consensus.app/papers/details/24705d5037e85bcb9d9863f1aabca040/), [Kunanayagam Pediatric CGT](https://consensus.app/papers/details/1c13548ad5be537a8451eed2c85ecd75/)* *#InstitutionalizingDay #CRISPR #AI #DrugDiscovery #AlphaFold #SingleCell #SpatialTranscriptomics #FDA #Regulatory #Standardization #IndustryStandard #BiomedicalAI #DailyReport* --- ## Sources (1차 출처 14개) [1] [Luo HMGN1 VP64 Fusion Base Editing — Advanced Science 2026](https://consensus.app/papers/details/dae4b67891e95542883889f62a6beba6/) [2] [Cho Multiplexed Base Editing Biocontainment — Nucleic Acids Research 2026](https://consensus.app/papers/details/35db4acf11255ff291d15b84ac3a7d62/) [3] [Lin Pharma AI 2026 Deals — GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/) [4] [Huynh AI Agents Drug Discovery — Drug Discovery Today 2026](https://consensus.app/papers/details/d47b0cf47a4f5055a7175a6fe09bb6e4/) [5] [Sarti AlphaFold Arity Map — Bioinformatics Advances 2026](https://consensus.app/papers/details/97d0d09907ed559998afbc1980b532f3/) [6] [Lin AlphaFold Oligomeric State — Protein Science 2026](https://consensus.app/papers/details/cff9b03d33d85cdf8d04f175b025a42c/) [7] [Chakraborty AlphaFold3 Impact — Frontiers in AI 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/) [8] [DenAdel Single-Cell FM Plateau — Nature Methods 2026](https://consensus.app/papers/details/f0f6bddc16985563ad8478918950e0f4/) [9] [Ji CAPTAIN Multimodal — Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/) [10] [Wang CellVQ — Nature Communications 2026](https://consensus.app/papers/details/89622623baa35922aaca1c5b88e6ce8b/) [11] [Zhang CosMx SCLC Spatial — Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/) [12] [Xiao Breast Cancer Spatial Multi-Omics — Clinical & Translational Oncology 2026](https://consensus.app/papers/details/860a4566c2235494b7a009a0b9a2c10f/) [13] [Shahzad FDA CGT Evidence — Clinical Pharmacology & Therapeutics 2026](https://consensus.app/papers/details/24705d5037e85bcb9d9863f1aabca040/) [14] [Kunanayagam Pediatric CGT — Pediatric Research 2026](https://consensus.app/papers/details/1c13548ad5be537a8451eed2c85ecd75/)
Research Pulse·2026-09-28
Research Pulse — 2026-09-28
28 journals × 7 topics · fibrosis · OXPHOS · ferroptosis · sarcopenia · senescence
Raw data + scoring: Daily Tech Digest (separate feed)
Request a Paid Brief